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There has been considerable interest in the role of synchronous brain activity
abnormalities in the pathophysiology of psychotic disorders and their relevance for
treatment; one index of such activity are EEG resting-state microstates. These reflect
electric field configurations of the brain that persist over 60–120ms time periods. A
set of quasi-stable microstates classes A, B, C, and D have been repeatedly identified
across healthy participants. Changes in microstate parameters coverage, duration and
occurrence have been found in medication-naïve as well as medicated patients with
psychotic disorders compared to healthy controls. However, to date, only two studies
have directly compared antipsychotic medication effects on EEG microstates either
pre- vs. post-treatment or between medicated and unmedicated chronic schizophrenia
patients. The aim of this study was therefore to directly compare EEG resting-state
microstates between medicated and medication-naïve (untreated) first-episode (FEP)
psychosis patients (mFEP vs. uFEP). We used 19-channel clinical EEG recordings to
compare temporal parameters of four prototypical microstate classes (A–D) within an
overall sample of 47 patients (mFEP n = 17; uFEP n = 30). The results demonstrated
significant decreases of microstate class A and significant increases of microstate class
B in mFEP compared to uFEP. No significant differences between groups were found
for microstate classes C and D. Further studies are needed to replicate these results in
longitudinal designs that assess antipsychotic medication effects on neural networks at
the onset of the disorder and over time during illness progression. As treatment response
and compliance in FEP patients are relatively low, such studies could contribute to better
understand treatment outcomes and ultimately improve treatment strategies.
Keywords: electroencephalography, resting-state, schizophrenia, antipsychotic, neuroleptic, untreated,
unmedicated, pathophysiology
INTRODUCTION
Delusions, hallucinations, disorganized speech, catatonic behavior, and negative symptoms form
the core of psychotic disorders [DSM-5 R©, (1)]. The lifetime prevalence of psychotic disorders is
estimated at 0.75% (2). Compared to the general population, patients’ life expectancy is estimated to
be shortened by 15–20 years due to increased physical morbidity (3). Patients’ everyday functioning
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such as independent living, productive activity, and social
functioning is often impaired, leading to high costs beyond
their medical treatment (4). Good functional outcomes were
found to be related to shorter duration of untreated psychosis
(5) which calls for timely and effective treatment at an early
illness stage. However, discontinuation rates within 18 months
of antipsychotic treatment due to inefficiency or intolerable side
effects were observed to be relatively high (64–82%) in psychotic
disorders (6) with a recovery rate estimated at only 13.5% (7).
This clearly calls for more research on antipsychotic medication
and how EEGmarkers and neural networks differentiate between
medicated and unmedicated patients with psychotic disorders.
Electroencephalography (EEG) is onemethod in neuroscience
research that offers several advantages. Apart from being
inexpensive, non-invasive, and easy to implement, EEG can
capture the fast-changing dynamics of neuronal networks with
high temporal resolution in frequency bands ranging from 1Hz
to up to 200Hz (8, 9). This allows EEG to depict coupling
patterns of neural activity that might not be captured by
functional Magnetic Resonance Imaging (10). There is a large
body of research that has studied neuronal network disruptions
in psychotic disorders using EEG methods and extensive reviews
exist on the topic (11–14).
The term “resting-state” refers to intrinsic patterns of the
awake state in which participants are not performing an explicit
mental or physical task (15) and are postulated to show the
underlying intrinsic mechanisms of the brain which influence
stimulus processing as well as behavioral phenomena (16). An
accumulation of evidence has shown that EEG resting-state
microstates are a suitable tool to study the temporal dynamics
of resting-state brain networks: EEG microstates are spatial
configurations of scalp global field power that remain stable
for a short period of time (60–120ms) and occur several
times per second (17, 18). These short-lasting, non-overlapping
configurations of brain electric states have been divided into four
prototypical microstate classes A, B, C, and D that each have a
different orientation of the scalp-electric field (19): Microstate
A has a left occipital to right frontal orientation, microstate B a
right occipital and left frontal, microstate C a symmetric occipital
to prefrontal and microstate D a symmetric frontocentral to
occipital orientation (17). These four classes explain 65–84% of
EEG data variance (20) and were shown to have high test-retest
reliability and cross-method consistency (21). The microstate
classes are described by three statistical parameters; the duration
of each class in milliseconds, mean number of occurrence
per second and percentage of time covered by each class (17).
Microstates were hypothesized to be the fundamental building
blocks of human information processing and were found to differ
across sex groups (22), over the course of development (17, 22)
and between different brain states such as sleep and wakefulness
(23, 24). Studies using simultaneous EEG-fMRI methods have
correlated microstate classes to different resting-state networks
(25, 26). Furthermore, abnormal patterns have been described
in various mental conditions (27–30), most notably in psychotic
disorders: Microstate differences across all classes were found
for medicated (31–35), as well as medication-naïve patients with
psychotic disorders (30, 36–38) compared to healthy controls,
as well as patients in the high-risk state of psychosis (31, 36,
39). Two recent meta-analyses found increased occurrence of
microstate C and decreased duration of microstate D to be
consistently reported across studies in medicated as well as
medication-naïve patients with psychotic disorders (40, 41).
So far, it is not clear whether and how antipsychotic
medication treatment plays a role in EEG resting-state
microstate abnormalities in patients with psychotic disorders.
Antipsychotics have been shown to modulate neural networks
in fMRI studies (42, 43) and to have effects on microstate
parameters by increasing the mean duration of all microstate
classes in healthy individuals (44). However, so far only two
studies investigated the effects of antipsychotic treatment
on EEG microstates in patients with psychotic disorders. A
cross-sectional study from more than two decades ago with
chronic schizophrenia patients reported antipsychotic treatment
to be negatively correlated with microstate duration in a
dose-dependent way and average microstate duration was
longer in unmedicated than medicated patients (45). Moreover,
increased duration of microstate classes A and D, and decreased
occurrence of microstate class C was reported in responders
vs. non-responder schizophrenia patients following 2–8 week
treatment with antipsychotics in a longitudinal design (37).
However, the latter findings were based on a small sample size (n
= 14) and have not yet been replicated.
The present study therefore aimed to investigate the effects
of antipsychotic treatment on EEG resting-state microstate
parameters by comparing medicated first-episode psychosis
patients (mFEP) to a control group of patients who were
medication-naïve (untreated first-episode psychosis; uFEP). Our
comparisons were set out to investigate differences in parameters
of microstate classes A-D that might be attributed to the
medication status of the two patient groups beyond the effect
of the disorder. As the results of previous studies have been
inconsistent so far, we based our study hypotheses on a recent
study by our group (36) in which we suggested that microstate A
and Bmay be state markers for psychotic disorders. We therefore
hypothesized antipsychotics to associate with microstate A and B
and these microstates to differentiate the two patient groups.
METHODS
The data used in this paper was collected in the FePsy project
(Früherkennung von Psychosen; Early Detection of Psychoses) of
the University of Basel Psychiatric Clinics (UPK) during the time
period from 2000–2013. The aim of the FePsy project was to
improve early detection and intervention of psychosis. The study
was approved by the local ethics committee and in accordance
with the Declaration of Helsinki. Riecher-Rössler et al. (46, 47)
provide a comprehensive overview of the FePsy study design.
Participants
All first-episode psychosis (FEP) patients included in the present
paper were help-seeking consecutive referrals to the FePsy clinic
at the psychiatric outpatient department of the University of
Basel Psychiatric Clinics (UPK). Upon inclusion in the FePsy
study, written informed consent was given by all participating
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TABLE 1 | Sample demographics.
mFEP uFEP
n = 17 n = 30 t/χ2 p d
Sex (M:F) 13:4 19:11 0.862 0.353 –
Age at diagnosis (years)
(mean [SD])
27.68 (5.1) 28.63 (7.5) −0.517* 0.608 0.148
BPRS (mean [SD]) 47.66 (7.15) 53.68 (10.84) −1.70 0.10 0.66
Total score
Depression/anxiety 9.45 (3.24) 11.70 (4.39) −1.54 0.13 0.58
Psychosis/thought
disturbance
10.64 (2.46) 12.13 (3.37) −1.33 0.19 0.50
Negative symptoms 5.41 (2.20) 5.72 (2.76) −0.34 0.74 0.12
Activation 6.73 (3.16) 7.28 (3.50) −0.45 0.65 0.16
Duration of illness
(months) (mean [SD])
24.83 (22.61) 23.77 (35.36) 0.11 0.91 0.04
Comorbidities (ICD-10) – 0.81** –
F10-F191 0 1
F30-F391 5 7
F40-F491 1 0
F60-F691 0 1
CPZ equivalent dose
(mean [SD])
210.29 (262.71) n/a – – –
Further medication – 1** –
Antidepressants 2 4
Anxiolytics 4 7
Mood stabilizers 0 0
Other 1 2
Current drug use – 0.44** –
Yes 11 20
No 5 4
Current alcohol use – 1** –
Yes 8 12
No 8 12
Cannabis use – 0.52** –
1)Earlier
Yes 9 18
No 7 5
2)Currently
Yes 6 9
No 11 18
Verbal IQ* (mean [SD]) 103 (16.04) 107.28 (14.34) −0.84 0.41 0.28
School education
(years) (mean [SD])
10.71 (3.25) 11.20 (3.22) −0.50 0.62 0.15
Education level – 0.84** –
Education ongoing 2 1
Primary school 1 1
Secondary school 9 11
Upper/specialized
secondary school
1 2
High school without
completion
0 2
High school 3 6
(Continued)
TABLE 1 | Continued
mFEP uFEP
n = 17 n = 30 t/χ2 p d
Current employment – 0.71** –
Yes 3 6
No 13 17
EEG total analysis time
(seconds) (mean [SD])
300.30 (74.83) 299.20 (44.72) 0.055 0.957 0.018
EEG explained variance
(%) (mean [SD])
77.43 (3.36) 77.36 (3.61) 0.073 0.942 0.020
mFEP, medicated first-episode psychosis patients; uFEP, untreated, medication-
naïve first-episode psychosis patients; BPRS, Brief Psychiatric Rating Scale; CPZ,
Chlorpromazine; SD, standard deviation; d, Cohen’s d effect size; *assessed with
the German version of the multiple choice vocabulary test [Mehrfach-Wortschatz-Test;
(52)]; **Fischer’s exact test applied. 1F10-F19, Mental and behavioral disorders due to
psychoactive substance use; F30-F39, Mood [affective] disorders; F40-F49, Neurotic,
stress-related and somatoform disorders; F60-F69, Disorders of adult personality and
behavior. Significance level is 0.05.
patients. The Basel Screening Instrument for Psychosis [BSIP;
Riecher-Rössler et al. (47, 48)] was used to determine the FEP
status, diagnostics were made according to ICD-10 (49), the
Brief Psychiatric Rating Scale [BPRS; (50, 51)] was applied to
assess patients’ symptom severity, and the German version of
the multiple choice vocabulary test [Mehrfach-Wortschatz-Test;
(52)] was used to assess verbal IQ. The status of medication-
naïve was defined by the absence of any lifetime antipsychotic
treatment and illness duration for both groups was calculated
based on the patient’s reports in hindsight of the very first
occurrence of psychotic symptoms with sufficient severity. As
Table 1 displays, intake of other medication did however occur
in the uFEP group.
Exclusion criteria were applied as follows; (1) age < 18 years;
(2) insufficient knowledge of German; (3) IQ < 70; (4) serious
medical or surgical illness; (5) previous episode of psychosis due
to substance abuse, and (6) psychotic symptomatology within a
clearly diagnosed affective or borderline personality disorder.
EEG Recording and Pre-processing
A standard clinical EEG protocol of 20min (incl. resting-
state, eyes opening, photostimulation, and hyperventilation) was
recorded by a trained lab assistant using 19 gold cup electrodes
(Nicolet Biomedical, Inc.) of the International 10–20 system and
referenced to linked ears. Participants were comfortably seated
in a quiet room. The first 8min of the entire clinical EEG
recording corresponded to a resting-state eyes-closed recording
which was used for the present analysis. During this, participants
were asked to open their eyes for 6 s every 3min to avoid
drowsiness. When behavioral or EEG signs of drowsiness (e.g.,
slow rolling eye movements, alpha drop-out, increased beta, or
theta activity) occurred, participants were asked to open their
eyes. The sampling rate was 256Hz and electrode impedances
were always kept below 5 kΩ .
Brain Vision Analyzer (Version 2.0, Brain Products GmbH,
Munich, Germany) was used for offline pre-processing. After
bandpass (IIR; 0.5–70Hz) and notch (50Hz) filters were
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FIGURE 1 | All performed steps of EEG pre-processing, microstate analysis, and statistical analysis. ICA, Independent Component Analysis; GFP, Global Field Power;
AAHC, Atomize-Agglomerate Hierarchical Clustering; *Interpolation was only performed for channels with severe artifacts across the whole recording.
applied, eyes-open epochs and epochs with prominent muscle
artifacts or bad EEG signals were removed manually upon
visual inspection by trained staff. After that, interpolation was
applied for channels with severe artifacts across the whole
recording and Extended Infomax ICA was used to remove
ocular muscle artifacts. The continuous EEG recording was then
divided into 2s segments and segments with residual artifacts
were removed semi-automatically and by means of visual
inspection based on consensus between at least two independent
reviewers. Re-referencing was applied with a common
average reference and the data was finally bandpass filtered
(FIR; 2–20 Hz).
Microstate Analysis
The Microstate Analysis plug-in (Version 0.3; downloaded
from http://www.thomaskoenig.ch/Download/EEGLAB_
Microstates/) for EEGLAB (53) version 13.6.5b in Matlab (54)
was used for the microstate analysis. First, the Global Field
Power (GFP) was calculated for each time point of the recording.
Since the signal-to-noise ratio is the highest for GFP peaks,
microstate configurations remain stable around these peaks (17).
Using Atomize-Agglomerate Hierarchical Clustering (AAHC),
individual microstate maps for GFP peaks only were calculated
for each participant based on the original momentary maps (55).
Four microstate classes have been described to explain 65–84%
(20) of the EEG variances. Based on this and for comparability
with previous studies on psychotic disorders, the number of
microstate clusters for the present study was also pre-set to four.
Groupmodel maps were calculated separately for both patient
groups using a permutation algorithm that minimized common
variance across subjects (19). Based on these group models, a
“grand-mean” model was calculated. The grand-mean model
was then class-labeled into microstates A–D by using minimal
Global Map Dissimilarity and model map norms from Koenig
et al. (17). Next, the class-labeled “grand-mean” model maps
were used as a template to assign the group model maps
to the four class-labeled grand-mean maps. As a final step,
the individual microstate maps were sorted according to the
class-labeled group model maps. Three parameters were then
extracted per microstate class: coverage (percentage of analysis
time covered by each microstate class), duration (the average
duration of a microstate class in milliseconds), and occurrence
per second (total number of each microstate class per second).
As the microstate toolbox ignores the first and last segment
of the EEG data, only non-truncated microstate parameters
are calculated. In addition, microstate transition probabilities
(observed minus expected) were calculated. Figure 1 depicts all
analysis steps.
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Statistical Analysis
A 4 (microstate class) × 2 (group) repeated measures
ANOVA was applied to assess the interactional effect for each
microstate parameter. Independent t-tests between the two
groups (mFEP vs. uFEP) were conducted in order to determine
group differences per parameter for each microstate class and
demographic variables.
All analyses were carried out using SPSS 25 and R (56).
Statistical tests in the present study are two-sided tests and
the statistical level was set at α = 0.05. When equal variances
could not be assumed, the Greenhouse-Geisser correction for
ANOVAs and the Welch-Satterthwaite method for the t-tests
was applied. Microstate results were corrected for multiple
comparisons within each parameter (57).
RESULTS
Group Characteristics
From a total of 59 FEP patients with available EEG data, 12
patients were excluded ex post facto due to unclear medication
status. Thus, a total of 47 participants were included in the
present analysis, consisting of 30 untreated, medication-naïve
patients with first-episode psychosis (uFEP) and 17 medicated
patients with first-episode psychosis (mFEP). There were no
statistically significant differences between the two groups in
age at diagnosis, sex distribution, illness duration (months), and
symptom severity score as assessed with the Brief Psychiatric
Rating Scale (51). Table 1 displays the demographics of the
two study groups and Table 2 gives an overview of the ICD-
10 diagnosis types per group which did not significantly differ
between the two groups either. Approximately, a mean of 5min
resting-state recording per subject were used for further analysis
(mFEPmean 300.3 s, and uFEPmean 299.2 s, respectively) which
equals ∼150 epochs of 2 s length per subject of each patient
group. If channels were interpolated, these did not exceed a
maximum of 4 channels per participant (mean 0.61, SD 1.00;
range 1–4 channels).
Microstate Parameters: Overall Results
Class-labeled group model maps were calculated separately for
each participant group and are shown in Figure 2. The average
global explained variance across both groups was 77.4% and
the EEG total analysis time (seconds) did not significantly differ
between groups (see Table 1).
Microstate Parameters: Between-Group
Differences
The microstate class x group interactions were significant for all
microstate parameters: coverage [F(3,135) = 11.603, p < 0.001,
ηp² = 0.205]; duration [F(2.414,108.616) = 7.698, p < 0.001, ηp²
= 0.146]; and occurrence [F(3,135) = 14.417, p < 0.001, ηp² =
0.243]. Follow-up t-tests indicated significant decreases of mFEP
compared to uFEP for microstate A coverage [t(39.8) = −3.87,
p = 0.001, d = −1.14], and occurrence [t(44.5) = −3.51, p =
0.003, d = −1.00]. No significant group differences were found
for microstate A duration [t(34.3) =−2.24, p= 0.094, d=−0.68].
Significant increases in the mFEP compared to uFEP group were
TABLE 2 | Overview of diagnosis types per group.
Type of psychotic disorder ICD-10 Code mFEP uFEP p
n = 17 n = 30 0.154
Paranoid schizophrenia F20.0 10 (58%) 14 (47%)
Hebephrenic schizophrenia F20.1 0 2 (7%)
Undifferentiated schizophrenia F20.3 1 (6%) 0
Other schizophrenia F20.8 1 (6%) 0
Schizophrenia unspecified F20.9 1 (6%) 4 (13%)
Persistent delusional disorders F22.0 2 (12%) 1 (3%)
Acute and transient psychotic
disorders
F23.x 1 (6%) 7 (23%)
Schizoaffective disorder,
depressive type
F25.1 0 2 (7%)
Unspecified non-organic
psychosis
F29 1 (6%) 0
mFEP, medicated first-episode psychosis patients; uFEP, untreated, medication-naïve
first-episode psychosis patients. Significance level is 0.05.
found for microstate B coverage [t(44.5) = 7.58, p < 0.001, d
= −2.16], duration [t(25.5) = 2.78, p = 0.040, d = 0.88], and
occurrence [t(35.6) = 7.39, p < 0.001, d = 2.22]. No significant
results were found for microstate C coverage [t(38.1) = −1.69,
p = 0.198, d = −0.50], duration [t(45.0) = −1.83, p = 0.146,
d = −0.52], and occurrence [t(27.5) = −0.79, p = 0.876, d =
−0.25], as well as microstate D coverage [t(35.8) = 0.22, p =
0.827, d= 0.07], duration [t(35.4) =−0.23 p= 0.817, d=−0.07],
and occurrence [t(31.5) = 0.63, p = 0.876, d = 0.19]. Figure 3
and Supplementary Table 1 display means for all microstate
parameters. The transition probabilities from class A to B [t(32.0)
= 3.97, p = 0.004, d = 1.21] and class C to B [t(44.9) = 5.97, p
< 0.001, d = 1.68] were increased in mFEP compared to uFEP.
The transition probabilities from class A to C [t(34.2) = −3.40, p
= 0.016, d = −1.03] and class C to A [t(43.7) = −4.69, p < 0.001,
d=−1.35] were decreased in mFEP compared to uFEP. Detailed
results are displayed in Supplementary Table 2.
DISCUSSION
We compared EEG microstate dynamics in medicated and
medication-naïve first-episode psychosis patients (mFEP and
uFEP, respectively). The microstate parameters coverage (%),
duration (ms) and occurrence/s of four microstate classes (A–D)
were compared between the two patient groups. We were able to
confirm the hypothesis of an association between antipsychotics
and microstate classes A and B.
We observed decreased microstate A coverage, and
occurrence in mFEP compared to uFEP. This finding is
underlined by a decrease of transitions from microstate C to A
in mFEP compared to uFEP. Previous studies in unmedicated
patients have reported an increase in microstate A compared to
healthy controls (19, 30, 36, 38). Here, we show a decrease in this
class in medicated patients, suggesting a beneficial association of
antipsychotics with microstate A. Converging with our results, a
decrease of microstate A was observed in medicated first-episode
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FIGURE 2 | Spatial configuration of the four microstate classes. Each row displays the four microstate classes (A–D) for both groups. Polarity is ignored. mFEP,
medicated first-episode psychosis patients; uFEP, untreated, medication-naïve first-episode psychosis patients.
FIGURE 3 | Microstates statistics. Group averages of the temporal parameters: (A) coverage, (B) duration and (C) occurrence. *p < 0.05, **p < 0.01, ****p < 0.0001.
patients compared to healthy controls (34) and microstate A was
positively correlated with psychopathological symptoms such as
depression (28) and negative symptoms of the avolition-apathy
domain (33) in patients with psychotic disorders.
Interestingly, another study observed an increase in the
same microstate class in more chronic medicated patients with
schizophrenia spectrum disorder with up to 10.5 years of illness
duration (SD 8.7) (32). Thus, illness progression (first-episode vs.
more chronic) may be an important factor to consider in future
studies of medication effects. Another modulatory aspect of
microstate A was demonstrated by Kikuchi et al. (37): Although
there was no pre- vs. post-effect after 2–8 weeks of antipsychotic
treatment—possibly due to the small sample size of n = 14
and relatively short follow-up intervals—they observed increased
microstate A in responders vs. non-responders.
Further between-group differences were observed for
microstate B in which coverage, duration, and occurrence were
increased in mFEP compared to uFEP. In addition, we observed
more transitions from microstates A and C to microstate B
in mFEP compared to uFEP. Compared to healthy controls,
previous studies in unmedicated patients showed a decrease
in microstate B (30, 38, 58). Again, the present study shows
an opposite effect in medicated patients which could be an
indication of a positive treatment effect for this class. This is
further underlined by Andreou et al. (31) in which medicated
first-episode patients also showed an increase in coverage of
microstate B. On the other hand, Baradits et al. (32) found a
decrease in all parameters of microstate B. However, inclusion
of medicated schizophrenia patients with an average illness
duration of 10.5 years in the latter study could again explain the
difference in findings. This is in line with the recent suggestion
that microstate B might be a specific state biomarker for
psychotic illness progression (36).
Despite the fact that several studies found changes in
microstate C between unmedicated (30, 37, 38) and medicated
patients with psychotic disorders (33, 34, 37, 59) compared to
healthy controls, we did not observe any significant differences
between mFEP and uFEP in the present study. The absence of a
difference might be explained by the fact that previous studies
have reported the same finding, i.e., increase in microstate C
compared to healthy controls, regardless of whether they assessed
medicated or medication-naïve patient samples. Therefore,
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it is conceivable that microstate C changes in patients are
independent of medication status; however, larger studies are
warranted to confirm our negative finding.
No significant differences in microstate D were observed
between the two groups either. This is somewhat surprising,
given that changes in microstate D are a central finding of
studies comparing (both medicated and unmedicated) patients
with psychotic disorders to healthy controls (19, 30, 32, 37, 38,
40, 59). Microstate D has further been associated with (positive)
psychotic symptoms: a decrease was observed during periods
of auditory hallucinations (60) and an increase in patients who
responded well to antipsychotic medication (37). However, a
study by Andreou et al. (31) comparing patients with FEP to
a high-risk group with a similar symptom profile observed no
differences in microstate D. The symptom severity scores of the
patients in the present study did not significantly differ, with
both groups being within the “markedly ill” range (61). This
could explain why no differences in microstate D were observed.
However, there is also an alternative explanation: We previously
suggested that microstate D serves as a trait marker for psychotic
disorders (36) in which case no effects of medication would be
expected. Furthermore, a study by da Cruz et al. (40) suggested
microstate D as endophenotype for psychosis in non-affected
siblings of schizophrenia patients. To this end, studies with larger
sample sizes are needed to further investigate medication effects
on microstate D in patients with psychotic disorders.
Response status is an important issue to be considered
in future studies investigating antipsychotic medication effects
since it differs between individual patients (62, 63). As already
mentioned, Kikuchi et al. (37) reported differences between
patients that were classified as responders vs. non-responders
to antipsychotic medication. However, their finding warrants
replication, given that it was based on a small sample size (n
= 7 per group). Unfortunately, it was not possible to trace
response history for patients included in the present study;
further studies should therefore investigate this issue. In addition,
studies with longitudinal within-subject designs should explore
the effects of antipsychotic medication treatment on EEG resting-
state microstates, their association with individual response
trajectories, as well as the role of patient baseline characteristics
on medication effects. Ultimately, such studies could set the
first steps into personalized medicine. This approach has been
suggested for major depressive disorders and attention deficit
disorders [for a review see Olbrich et al. (64)]. EEG resting-state
microstates are particularly suited for this purpose, given that
they have been suggested to be promising candidate biomarkers
in psychotic disorders (32, 36, 40).
Further limitations of the present study have to be considered
as well. Although the changes observed in medicated patients are
in the expected direction, i.e., in the opposite direction of changes
reported in previous studies comparing unmedicated patients
to healthy controls, the inclusion of a matched healthy control
sample would have been advantageous in completing the picture.
Besides a healthy control group, a longitudinal design would have
enabled us to confirm that the observed effects in medicated
patients indeed correspond to a “normalization” of microstate
parameters. A larger sample size than the one used here would
have further increased statistical power of the results. Studies with
high power are more likely to find true effects, e.g., correlation
coefficients are estimated with a higher precision when sample
sizes are increased (65). Moreover, it is due to the small sample
size that we could not explore correlations between the four
factors of the BPRS (with which the patients’ symptom severities
were measured) and the three parameters coverage, duration and
occurrence of each microstate class A, B, C, and D. This could
therefore be considered as a further limitation of this study.
In addition, cautiousness is warranted in the interpretation of
our results, as a decrease or increase of a given parameter does not
necessarily correspond to a “good” or “bad” outcome. Previous
studies comparing first-episode patients (FEP), ultra-high-risk
for psychosis patients and/or unaffected siblings of patients,
and healthy controls have demonstrated that microstate changes
do not always follow a linear pattern across different stages of
psychotic disorders (31, 36, 40). Moreover, it has been suggested
that some of the observed changes may reflect compensatory
mechanisms rather than a deficit (31, 40). A further limitation
of our study regards information which was not known for our
sample and could have acted as confounding factor. This includes
potentially different effects of individual antipsychotics (i.e.,
first vs. second generation antipsychotics) on EEG, medication
duration, antipsychotic side effects, medication compliance,
markers of socio-economic functioning, nicotine use, as well
as the time of day of the EEG recording. Further confounding
factors could have been age and sex distributions, as well as illness
duration, drug consumption or other medication. However, all
these variables did not significantly differ between groups.
Furthermore, two methodological points should be
considered as well. First, based on previously established
norms by Koenig et al. (17) the present study assessed four
microstate classes. However, as suggested by Custo et al. (26)
an increased number of microstates with a 7-map model might
improve the explained global variance (20). Nevertheless,
using four microstate classes has the important advantage of
allowing direct comparisons of our results with previous studies
in patients with psychotic disorders and high psychosis risk.
Together with our relatively high global explained variance
of 77%, we therefore deem our current method appropriate.
As a second methodological limitation, it should be kept in
mind that different pre-processing strategies, data selection
methods and smoothing parameters (20) as well as differences in
microstate analysis steps [e.g., the template used for microstate
class assignment (21)] may influence microstate temporal
parameters. In our study, we chose pre-processing and analysis
parameters such as to ensure maximum comparability with a
previous study by our group (36) but there may be differences
compared to other studies. For future research in the field of
EEG microstates, it would be very useful to harmonize methods
in order to promote comparability.
CONCLUSION
Our findings suggest an association of antipsychotic medication
with microstates A and B in first-episode psychosis patients.
Further studies with large sample sizes and longitudinal
designs are needed that directly compare medicated and
medication-naïve patients as well as healthy controls, in order to
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investigate antipsychotic medication effects on neural networks
over time and throughout illness progression.
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